A Europe-based venture capital firm founded by entrepreneurs with extensive life sciences and biotechnology experience focuses exclusively on novel therapeutics. The firm invests at the earliest stages of development, from Seed through late preclinical programs, typically supporting assets through clinical proof of concept and seeking exits following meaningful clinical validation. The firm is currently investing from an existing fund primarily focused on Europe and is nearing the end of its deployment period. The investor plans to raise its next fund in the near term, with an anticipated stronger focus on U.S. opportunities.
The firm typically makes initial equity investments ranging from $3 million to $5 million and may also consider convertible loan structures where appropriate. It has the capacity to invest approximately $15 million to $20 million per company over the life of an investment. The firm participates in both company creation and investment syndicates alongside other specialist biotech investors.
The investor focuses exclusively on therapeutics and is indication- and modality-agnostic. It seeks novel drug candidates with strong scientific rationale, differentiated mechanisms of action, significant unmet medical needs, and high commercial potential. The firm’s primary considerations are the stage of development, scientific differentiation, and commercial opportunity rather than specific therapeutic areas or modalities.
The firm sources opportunities through its global network of biotech founders, academic researchers, and entrepreneurial management teams. Following investment, it works closely with portfolio companies to execute R&D strategies, optimize capital allocation, and prepare for future financing rounds or strategic transactions. While historically focused on Europe, the firm takes a geographically opportunistic approach and evaluates opportunities based on scientific merit, valuation, and potential risk-adjusted returns.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
